Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Titel:
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Auteur:
Sequist, Lecia V Han, Ji-Youn Ahn, Myung-Ju Cho, Byoung Chul Yu, Helena Kim, Sang-We Yang, James Chih-Hsin Lee, Jong Seok Su, Wu-Chou Kowalski, Dariusz Orlov, Sergey Cantarini, Mireille Verheijen, Remy B Mellemgaard, Anders Ottesen, Lone Frewer, Paul Ou, Xiaoling Oxnard, Geoffrey